Nvidia’s expanded presence in AI-driven healthcare and robotics highlights its computing platform as a foundation for cross-industry innovation. (BizTrendWire Insight)
Nvidia highlighted key initiatives involving artificial intelligence and robotics in early 2026.
The company discussed both a strategic lab partnership and robotics applications in life sciences.
On January 13, Nvidia and Eli Lilly announced a new AI co-innovation lab for drug discovery.
The lab will combine expertise in pharmaceuticals and AI computing.
Nvidia and Lilly plan to invest up to $1 billion over five years in talent, infrastructure and compute.
The initiative was unveiled at the J.P. Morgan Healthcare Conference in San Francisco.
The lab aims to unite biological research and AI model development under one framework.
Meanwhile, Nvidia technology is being used to support automation in cell therapy manufacturing.
Multiply Labs uses Nvidia’s Omniverse and Isaac Sim for robotics and digital twin simulations.
These systems help automate tasks and improve precision in laboratory processes.
Robotics automation can cut cost per cell therapy dose by more than 70%, reducing it to about $25,000–$35,000.
Automation also increases throughput up to 100 times per square foot of facility space.
Both announcements reflect Nvidia’s role in AI computing platforms.
The drug discovery lab and robotics platforms use Nvidia AI stacks to address complex rules in life sciences.
Source: Nvidia Official Blog – AI Drug Discovery Lab
Nvidia Official Blog – Robotics for Cell Therapy
